| |
Turnkey pharmaceutical manufacturing facilities and a 75% property tax exemption make expanding your bioscience business to Puerto Rico easier than ever. It's not what's next, it's where. Puerto Rico. 
|
|
Today’s Big NewsMay 23, 2024 |
|
Thursday, June 6, 2024 | 11am ET / 7am PT Assessment of antibody off-target reactivity is a regulatory requirement for clinical development. However, conventional screening methods are often ineffective in screening newer therapeutic modalities, and their predictive value for in vivo safety and toxicity is poor. Join us for a look at the new alternatives for success. Register now. 
|
|
| By Zoey Becker All but one dose of the company's popular ADHD medicine are now marked as available on the FDA's shortage list. Meanwhile, some generics to Adderall and of Takeda' Vyvanse are still struggling with supply issues. |
|
|
|
By Annalee Armstrong Cytokinetics has now all but assured that a buyout is nowhere in the near future with a $575 million Royalty Pharma funding deal that drew the ire of investors. |
By Conor Hale A head-to-head study from Medtronic showed that its minimally invasive approach to reaching tissues in the lung suspected of harboring cancer could be just as effective as the current standard of care. |
By Andrea Park Ahead of the FDA’s decision on Bristol Myers Squibb’s schizophrenia treatment KarXT, the Big Pharma has kicked off a campaign this week to improve education around and destigmatize the mental illness while also providing helpful resources for patients. |
|
Wednesday, June 12, 2024 | 11am ET / 8am PT If you are a company developing gene therapies, don’t miss this opportunity to learn about containment and aseptic filling solutions – how to prepare for fill finish early and ensure products are ready to ship immediately upon approval, providing life-saving drugs to patients as quickly as possible. Register now. 
|
|
By Fraiser Kansteiner Women represented by six law firms who previously filed lawsuits against J&J over talc claims have filed a proposed class action lawsuit in U.S. federal court in New Jersey. In the latest turn in the legal saga, lawyers argued J&J used a series of “fraudulent maneuvers” to avoid paying out compensation to cancer victims and their families. |
By Annalee Armstrong Takeda has taken a trip all the way to Shanghai to find just the right kind of glue to stick together a $1.2 billion biobucks deal for new candidates in oncology, neuroscience and inflammation. |
By Kevin Dunleavy In the continuation of a decade-long legal battle, a Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay a combined $916 million to the state for failing to warn patients about the ineffectiveness of their blood thinner Plavix in some non-white patients. The companies plan to appeal. |
By James Waldron Tango Therapeutics has discarded one of its cancer drugs on the dancefloor after the USP1 inhibitor was linked to reports of liver toxicity in a phase 1 trial. |
By Kevin Dunleavy MilliporeSigma, the Massachusetts-based contract manufacturing arm of Merck KGaA, is increasing its presence in the gene therapy manufacturing field as it has signed an agreement to acquire Mirus Bio for $600 million. The Wisconsin-based company develops and commercializes transfection reagents, which allow genetic material to be incorporated into cells. |
By Helen Floersh Palisade Bio’s PDE4 inhibitor to treat the inflammatory bowel disease ulcerative colitis appears to be effective in mice and doesn't cause toxicity in dogs, study findings presented at the annual Digestive Disease Week conference. |
Fierce podcasts Don’t miss an episode |
| This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
|
Wednesday, June 19, 2024 |10am ET / 7am PT Join us on Monday, June 19, 2024 for one hour all about oral cyclic peptide drug development. Smaller breakthroughs in our own labs demonstrate results worth registering for. 
|
|
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
